Citichem India Limited reported a net profit of ₹1.00 crore for the financial year ended March 31, 2026, a decline of 18.5% compared to ₹1.23 crore in the previous year. The company's revenue from operations fell 49.3% to ₹9.48 crore from ₹18.70 crore in FY25, primarily due to reduced sales in its chemicals segment. The Board of Directors approved the audited standalone financial results at a meeting held on May 30, 2026.

The company’s total revenue for FY26 stood at ₹15.48 crore, significantly lower than ₹54.73 crore in the preceding year. This reduction was driven by a substantial decrease in other operating income, which fell to ₹5.30 crore from ₹35.68 crore. Despite the top-line contraction, the company maintained a positive EBITDA of ₹2.02 crore, slightly up from ₹1.98 crore in FY25. However, finance costs increased to ₹58.37 lakh from ₹30.61 lakh, impacting the bottom line.

Financial Performance

Balance Sheet Highlights

The company’s balance sheet size contracted, with total assets decreasing to ₹54.80 crore as of March 31, 2026, from ₹69.92 crore a year earlier. Shareholders' equity improved marginally to ₹21.10 crore, driven by an increase in reserves and surplus to ₹14.30 crore. Short-term borrowings rose to ₹7.72 crore from ₹4.77 crore, while trade payables reduced significantly to ₹24.55 crore from ₹42.76 crore.

Cash and cash equivalents depleted to ₹65.59 lakh from ₹4.46 crore at the end of FY25. The contingent liabilities remained stable at ₹21.44 crore, comprising income tax demands. The auditors, NGST & Associates, issued an unmodified opinion on the financial results.

CITICHEM India Limited has issued a formal response to BSE Limited regarding an inquiry into recent price movements of its securities. The Mumbai-based company addressed concerns raised by the exchange's surveillance department through an official communication dated April 14, 2026.

BSE Surveillance Inquiry Response

The company received a price movement clarification request from BSE's Surveillance Department on April 13, 2026, referenced as L/SURV/ONL/PV/APJ/2026-2027/3704. This inquiry sought clarification regarding significant movement in the price of CITICHEM India Limited's securities on the exchange.

Regulatory Compliance Confirmation

CITICHEM India Limited, through Managing Director Arif Esmail Merchant, confirmed comprehensive compliance with regulatory disclosure requirements. The company stated that all necessary disclosures have been made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations 2015.

Key compliance aspects highlighted include:

• All required disclosures made within stipulated timelines
• Price sensitive information disclosed to stock exchanges as required
• Operational and performance-related information shared appropriately
• No undisclosed events that could impact stock price behavior

Management Statement

The response emphasized that the company currently has no information or events requiring disclosure that may have a bearing on price or volume behavior in its securities. This statement provides clarity to market participants regarding the company's transparency in regulatory compliance.

Corporate Information

CITICHEM India Limited operates from its corporate office located at 512, Yogeshwar Premises, 5th Floor, 135 Kazi Sayed Street, Masjid Bunder (W), Mumbai. The company maintains regular communication channels with stakeholders through its official website and designated contact points for investor relations.